A5043180672- Phagocytosis and Immune Regulation
- Cancer Mechanisms and Therapy
- Pancreatic and Hepatic Oncology Research
- Microtubule and mitosis dynamics
- Renal cell carcinoma treatment
- Bioinformatics and Genomic Networks
- Cancer Cells and Metastasis
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Chromatin Remodeling and Cancer
- Neuroendocrine Tumor Research Advances
- Metabolism, Diabetes, and Cancer
- Cancer, Hypoxia, and Metabolism
Genome Institute of Singapore
2021-2023
Agency for Science, Technology and Research
2023
National University Cancer Institute, Singapore
2020-2021
National University of Singapore
2020-2021
AXL is a receptor tyrosine kinase that often overexpressed in cancers. It contributes to pathophysiology cancer progression and therapeutic resistance, making it an emerging target. The first-in-class inhibitor bemcentinib (R428/BGB324) has been granted fast track designation by the U.S. Food Drug Administration (FDA) STK11-mutated advanced metastatic non-small cell lung was also reported show selective sensitivity towards ovarian cancers (OC) with Mesenchymal molecular subtype. In this...
e15640 Background: AXL is a receptor tyrosine kinase that often overexpressed in many cancers. It contributes to tumor progression, metastasis and drug resistance through activating downstream signaling cascades, making it an emerging therapeutic target. The first-in-class inhibitor R428 (BGB321) was approved by the FDA for treatment of relapsed or refractory acute myeloid leukemia. also reported show selective sensitivity towards ovarian cancers (OC) with Mesenchymal (Mes) molecular...
Abstract AXL is a receptor tyrosine kinase that often overexpressed in many cancers. It contributes to tumor progression, metastasis and drug resistance through activating downstream signaling cascades, making it an emerging therapeutic target. Moreover, the first-in-class inhibitor R428 (BGB321) was lately approved by FDA for treatment of relapsed or refractory acute myeloid leukemia. Previously, also reported show selective sensitivity towards ovarian cancers with Mesenchymal molecular...
Abstract AXL is a receptor tyrosine kinase that often overexpressed in cancers. It contributes to pathophysiology cancer progression and therapeutic resistance, making it an emerging target. The first-in-class inhibitor bemcentinib (R428/BGB324) was approved for treatment of acute myeloid leukaemia also reported show selective sensitivity towards ovarian cancers (OC) with Mesenchymal molecular subtype. In this study, we further explored AXL’s role mediating DNA damage responses by using OC...